Pfizer

Organization

On 4 shows in Health & Science this week · 4.9× usual · most on Huberman Lab

Pfizer Inc. is an American multinational pharmaceutical and biotechnology company headquartered in New York City. Founded in 1849, it researches, develops, manufactures, and commercializes medicines and vaccines across multiple therapeutic areas.

Rank this week

#52▲22
#41 over 30 days

Share of the conversation

0.9‰
4.9× usual level

1.1‰ of what listeners heard

Reach this week

4 shows
4 episodes · ~274k plays

Tone this week

Neutral
  • Neutral 3

Share of the conversation

Mentions of Pfizer per 1,000 mentions of anything, 7-day rolling, health & science.

0.0‰0.5‰1‰1.5‰usual level · 0.19‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Aug 310.24‰1
Sep 140.23‰1
Sep 170.52‰1
Oct 10.22‰1
Oct 40.46‰1
Oct 210.21‰1
Oct 260.43‰1
Oct 300.49‰1
Nov 120.18‰1
Nov 130.36‰1
Nov 150.55‰1
Nov 160.88‰2
Nov 171.01‰1
Nov 201.07‰2

Why is it trending?· Last 7 days

Pfizer faces pipeline, safety, China competition and vaccine-effectiveness scrutiny

On BioCentury This Week, Lauren Martz discussed Pfizer sharing upside from its $10 billion obesity program after acquiring Metsera, as the obesity field evolves.[1]

On The Readout Loud, Damian Garda highlighted CEO Albert Bourla saying Pfizer’s future competitors may all be Chinese pharmaceutical companies.[2]

On Biotech Hangout, Brian Skorney discussed Pfizer licensing an in vivo CAR-T program in China for up to $2.6 billion, while questioning the transparency of such deals.[3]

On Breaking Biotech, Matthew Cloutier noted that Pfizer acquired Global Blood Therapeutics, but its sickle-cell drug was pulled over safety concerns.[4]

On Huberman Lab, Paul Stamets said his studies showed reduced adverse reactions to Pfizer and Moderna vaccines and argued this could encourage vaccination; Andrew Huberman asked whether blunted inflammation explained it.[5][6]

Sources · 6 moments

  1. 1.
    BioCentury This Week · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
    Lauren Martz · Nov 17 · Listen at 5:50 ↗
    “Life Sciences. Remember, they acquired Claris some years ago. So yeah, as they do oftentimes, they support late -stage testing with cash and get some upside in return. And it's the second deal this week for Blackstone. Pfizer last week reve”
  2. 2.
    The Readout Loud · 422: FDA's search for a new leader, and China's largest drugmakers
    Damian Garda · Nov 20 · Listen at 5:57 ↗
    “moment as being like an overnight sensation. Obviously, it's not many of these companies trace their origins back more than five decades. But it certainly has accelerated in recent years. And there's no reason to believe that it would slow”
  3. 3.
    Biotech Hangout · Episode 204 - November 20, 2026
    Brian Skorney · Nov 20 · Listen at 36:33 ↗
    “And then a third BioBucks deal I'll mention is Pfizer did a China licensed... deal for an in vivo CAR-T for three programs in the INI and autoimmune space for up to $2.6 billion. So again, I'd love to open this up briefly, but we're getting”
  4. 4.
    Breaking Biotech · 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026
    Matthew Cloutier · Nov 15 · Listen at 5:55 ↗
    “We covered Global Blood Therapeutics for a while too, and they had a therapy as well. And that company was eventually acquired by by Pfizer. The drug was pulled though due to some safety concerns, but patients are basically left with taking”

Written by AI from the cited moments; every quote is checked against the transcript.

Who is saying what about Pfizer

Verified quotes from the last 90 days: who made the most claims, and which way they leaned.

Discussed alongside

Names that come up in the same conversations as Pfizer.

See 5 more with Pro

Embed this

Paste this on your site to show Pfizer's current trend:

<iframe src="https://podlume.ai/embed/e/pfizer" width="360" height="220" style="border:0" loading="lazy" title="Pfizer on PodLume Trends"></iframe>